Memorial Sloan Kettering Cancer Center Updates in Hepatopancreatobiliary Malignancy 2025

Description

+ Include: 47 Videos (.mp4) + 47 Subtitles (.vtt) + 1 PDFs, size: 11.3 GB

+ Target Audience: surgical oncologists and hepatologists

+ Sample video: contact me for sample video

+ Information:

1. Overview

The Memorial Sloan Kettering Cancer Center Updates in Hepatopancreatobiliary Malignancy 2025 focuses on the latest innovations in managing metastatic colorectal cancer and pancreatic cancer. The course covers evolving surgical strategies, novel therapeutics, and emerging biomarkers for both resectable and unresectable disease. Course Dates: November 20–21, 2025

2. Learning Objectives

• Evaluate the role of hepatic arterial infusion (HAI) chemotherapy and systemic therapies in adjuvant and neoadjuvant settings.

• Debate surgical versus non-surgical approaches for resectable and unresectable liver metastases, including ablation and transplantation.

• Analyze the utility of circulating tumor DNA (ctDNA) and molecular profiling in prognosis and treatment selection.

• Discuss the integration of novel immunotherapies, vaccines, and targeted agents into HPB malignancy care.

• Implement multidisciplinary strategies for managing complex cases of early-onset colorectal cancer and pancreatic adenocarcinoma.

3. Target Audience

Best for surgical oncologists and hepatologists who want updates on HPB malignancies, advanced surgical techniques, and systemic therapies.

4. Topics

1. Ablation vs Resection for Small Tumors

2. Advanced Endoscopy

3. Advanced PDAC

4. ALPPS- Is There Still a Role

5. Biomarkers, ctDNA

6. Changing Demographics of Colorectal Cancer- Young Onset CRC

7. Clinical Genomics, Screening

8. Cysts and Interception

9. Debate- Resectable PDAC – Surgery First vs. Neoadjuvant

10. Defining Resectable Disease- Technical and Biologic Factors

11. Diagnosis & Imaging – Panel Discussion and Q&A

12. Emerging Role of Immunotherapy

13. Epidemiology, Early Onset

14. HAI Chemotherapy- Results in the Adjuvant Setting

15. HAI FUDR — Updated Results and Conversion Systemic-Regional Therapy

16. Histotripsy- What is the Real Benefit

17. Homologous Repair Deficiency

18. Imaging in Metastatic Colorectal Cancer- Diagnosis and Assessing Treatment Response

19. Introduction – Panel Discussion and Q&A

20. Is ctDNA a Helpful Prognostic Tool in Resectable Colorectal Cancer Liver Metastasis

21. Liver Confined Disease- Updated Results of Resection

22. Liver Resection with Extrahepatic Metastatic Disease- Yes or No

23. Liver Transplantation- What is the Real Benefit

24. Metastatic Disease — How Do I Treat

25. MULTIDISCIPLINARY CASE PRESENTATIONS- Lesson from the Clinic

26. Neoadjuvant Treatment for Pancreatic Cancer

27. Novel Imaging, PET

28. Novel Immunotherapies (Beyond Vaccines)

29. Novel Therapeutics and Targeted Agents

30. Novel Therapies & The Future – Panel Discussion and Q&A

31. Pathology, Genomics, Testing

32. RAS Biology and Treatment

33. Resectable Liver Disease – Panel Discussion and Q&A

34. Resectable PDAC

35. Resectable, Borderline, & More – Panel Discussion and Q&A

36. Robotic Technical Pearls (Liver, HAI)

37. Role of Adjuvant-Neoadjuvant Systemic Therapy

38. Role of EBRT

39. Role of Molecular Profiling in Resectable Colorectal Cancer Liver Metastasis

40. Selecting First-Line Systemic Therapy for Metastatic Colorectal Cancer in 2025

41. Surgical Innovation, Prehab

42. Synchronous Disease- Chemotherapy First vs. Resection First

43. Systemic Therapies – Panel Discussion and Q&A

44. Two-Stage Hepatic Resection

45. Unresectable Liver Confined Disease – Panel Discussion and Q&A

46. Vaccines- Personalized, Off the Shelf

47. Y90 Radioembolization- Is There a Benefit